Brokerages Set Catalent, Inc. (NYSE:CTLT) Target Price at $52.46

Shares of Catalent, Inc. (NYSE:CTLT) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $52.46.

A number of analysts recently weighed in on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. UBS Group reaffirmed a “neutral” rating and set a $63.50 price objective (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. StockNews.com started coverage on shares of Catalent in a research note on Friday, April 19th. They set a “sell” rating on the stock. Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Finally, Barclays upped their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Catalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after acquiring an additional 365,648 shares during the last quarter. Capital World Investors boosted its stake in Catalent by 6.1% during the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares during the last quarter. Nomura Holdings Inc. lifted its stake in Catalent by 149.4% in the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after buying an additional 6,881,914 shares in the last quarter. Cadian Capital Management LP lifted its stake in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares in the last quarter. Finally, Barclays PLC lifted its stake in Catalent by 41.7% in the third quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock valued at $218,440,000 after buying an additional 1,412,058 shares in the last quarter.

Catalent Stock Down 0.3 %

Shares of CTLT opened at $55.81 on Friday. The company has a 50-day simple moving average of $56.76 and a 200-day simple moving average of $48.53. The firm has a market capitalization of $10.10 billion, a P/E ratio of -8.21, a P/E/G ratio of 6.04 and a beta of 1.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. Catalent has a 52 week low of $31.45 and a 52 week high of $60.20.

Catalent (NYSE:CTLT) last posted its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business’s revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 EPS. On average, equities research analysts expect that Catalent will post 0.28 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.